Oncolytic Virotherapy

Overview

Journal Nat Biotechnol

Specialty Biotechnology

Date 2012 Jul 12

PMID 22781695

Citations 780

Authors

Stephen J Russell

Kah-Whye Peng

John C Bell

Affiliations

Soon will be listed here.

Abstract

Oncolytic virotherapy is an emerging treatment modality that uses replication-competent viruses to destroy cancers. Recent advances include preclinical proof of feasibility for a single-shot virotherapy cure, identification of drugs that accelerate intratumoral virus propagation, strategies to maximize the immunotherapeutic action of oncolytic viruses and clinical confirmation of a critical viremic threshold for vascular delivery and intratumoral virus replication. The primary clinical milestone has been completion of accrual in a phase 3 trial of intratumoral herpes simplex virus therapy using talimogene laherparepvec for metastatic melanoma. Key challenges for the field are to select 'winners' from a burgeoning number of oncolytic platforms and engineered derivatives, to transiently suppress but then unleash the power of the immune system to maximize both virus spread and anticancer immunity, to develop more meaningful preclinical virotherapy models and to manufacture viruses with orders-of-magnitude higher yields than is currently possible.

Citing Articles

Current Landscape and Future Directions in Cancer Immunotherapy: Therapies, Trials, and Challenges.

Bandara S, Raveendran S Cancers (Basel). 2025; 17(5).

PMID: 40075668 PMC: 11899461. DOI: 10.3390/cancers17050821.

A novel oncolytic vaccinia virus with multiple gene modifications involved in viral replication and maturation increases safety for intravenous administration while maintaining proliferative potential in cancer cells.

Okita G, Suenaga K, Sakaguchi M, Murakami T PLoS One. 2025; 20(3):e0312205.

PMID: 40048445 PMC: 11884718. DOI: 10.1371/journal.pone.0312205.

Ferroptosis enhances the therapeutic potential of oncolytic adenoviruses KD01 against cancer.

Li W, Ji T, Ye J, Xiong S, Si Y, Sun X Cancer Gene Ther. 2025; .

PMID: 40033102 DOI: 10.1038/s41417-025-00882-z.

Decorin: matrix-based pan-cancer tumor suppressor.

Appunni S, Saxena A, Ramamoorthy V, Zhang Y, Doke M, Nair S Mol Cell Biochem. 2025; .

PMID: 39954173 DOI: 10.1007/s11010-025-05224-z.

Tumor microbiome: roles in tumor initiation, progression, and therapy.

Zhang S, Huang J, Jiang Z, Tong H, Ma X, Liu Y Mol Biomed. 2025; 6(1):9.

PMID: 39921821 PMC: 11807048. DOI: 10.1186/s43556-025-00248-9.

References

Mader E, Maeyama Y, Lin Y, Butler G, Russell H, Galanis E . Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res. 2009; 15(23):7246-55. PMC: 2787715. DOI: 10.1158/1078-0432.CCR-09-1292. View

Ong H, Hasegawa K, Dietz A, Russell S, Peng K . Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther. 2006; 14(4):324-33. DOI: 10.1038/sj.gt.3302880. View

Schoggins J, Wilson S, Panis M, Murphy M, Jones C, Bieniasz P . A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011; 472(7344):481-5. PMC: 3409588. DOI: 10.1038/nature09907. View

Bridle B, Hanson S, Lichty B . Combining oncolytic virotherapy and tumour vaccination. Cytokine Growth Factor Rev. 2010; 21(2-3):143-8. DOI: 10.1016/j.cytogfr.2010.02.009. View

Kottke T, Hall G, Pulido J, Diaz R, Thompson J, Chong H . Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J Clin Invest. 2010; 120(5):1551-60. PMC: 2860921. DOI: 10.1172/JCI41431. View

Patel B, Dey A, Ghorani E, Kumar S, Malam Y, Rai L . Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights. Mol Ther. 2011; 19(6):1034-40. PMC: 3129803. DOI: 10.1038/mt.2011.44. View

Kelly E, Russell S . MicroRNAs and the regulation of vector tropism. Mol Ther. 2008; 17(3):409-16. PMC: 2835080. DOI: 10.1038/mt.2008.288. View

Barton K, Stricker H, Brown S, Elshaikh M, Aref I, Lu M . Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther. 2008; 16(10):1761-9. PMC: 3127288. DOI: 10.1038/mt.2008.172. View

Martuza R, Malick A, Markert J, Ruffner K, Coen D . Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991; 252(5007):854-6. DOI: 10.1126/science.1851332. View

10.

Guedan S, Rojas J, Gros A, Mercade E, Cascallo M, Alemany R . Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther. 2010; 18(7):1275-83. PMC: 2911260. DOI: 10.1038/mt.2010.79. View

11.

Senac J, Doronin K, Russell S, Jelinek D, Greipp P, Barry M . Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther. 2009; 21(2):179-90. PMC: 2829453. DOI: 10.1089/hum.2009.082. View

12.

Jacobs A, Voges J, Reszka R, Lercher M, Gossmann A, Kracht L . Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet. 2001; 358(9283):727-9. DOI: 10.1016/s0140-6736(01)05904-9. View

13.

Ganesh S, Gonzalez-Edick M, Gibbons D, Van Roey M, Jooss K . Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin Cancer Res. 2008; 14(12):3933-41. DOI: 10.1158/1078-0432.CCR-07-4732. View

14.

Tao N, Gao G, Parr M, Johnston J, Baradet T, Wilson J . Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther. 2001; 3(1):28-35. DOI: 10.1006/mthe.2000.0227. View

15.

Stepkowski S . Molecular targets for existing and novel immunosuppressive drugs. Expert Rev Mol Med. 2003; 2(4):1-23. DOI: 10.1017/S1462399400001769. View

16.

Lewis J, Brown E, Duncan P . Approaches to the release of a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines. Dev Biol (Basel). 2006; 123:165-76. View

17.

Vandevenne P, Sadzot-Delvaux C, Piette J . Innate immune response and viral interference strategies developed by human herpesviruses. Biochem Pharmacol. 2010; 80(12):1955-72. DOI: 10.1016/j.bcp.2010.07.001. View

18.

Hashizume H, Baluk P, Morikawa S, McLean J, Thurston G, Roberge S . Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000; 156(4):1363-80. PMC: 1876882. DOI: 10.1016/S0002-9440(10)65006-7. View

19.

Fang J, Nakamura H, Maeda H . The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2010; 63(3):136-51. DOI: 10.1016/j.addr.2010.04.009. View

20.

Rudin C, Poirier J, Senzer N, Stephenson Jr J, Loesch D, Burroughs K . Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clin Cancer Res. 2011; 17(4):888-95. PMC: 5317273. DOI: 10.1158/1078-0432.CCR-10-1706. View